Small molecule telomerase inhibitors are also potent inhibitors of telomeric C-strand synthesis

  1. Thomas R. Cech1,2,3
  1. 1BioFrontiers Institute, University of Colorado Boulder, Boulder, Colorado 80303, USA
  2. 2Department of Biochemistry, University of Colorado Boulder, Boulder, Colorado 80303, USA
  3. 3Howard Hughes Medical Institute, University of Colorado Boulder, Boulder, Colorado 80303, USA
  1. Corresponding author: thomas.cech{at}colorado.edu
  1. Handling editor: Eric Phizicky

  • 4 Present address: Department of Biochemistry, University of Regensburg, 93053 Regensburg, Germany

Abstract

Telomere replication is essential for continued proliferation of human cells, such as stem cells and cancer cells. Telomerase lengthens the telomeric G-strand, while C-strand replication is accomplished by CST–polymerase α–primase (CST–PP). Replication of both strands is inhibited by formation of G-quadruplex (GQ) structures in the G-rich single-stranded DNA. TMPyP4 and pyridostatin (PDS), which stabilize GQ structures in both DNA and RNA, inhibit telomerase in vitro, and in human cells they cause telomere shortening that has been attributed to telomerase inhibition. Here, we show that TMPyP4 and PDS also inhibit C-strand synthesis by stabilizing DNA secondary structures and thereby preventing CST–PP from binding to telomeric DNA. We also show that these small molecules inhibit CST–PP binding to a DNA sequence containing no consecutive guanine residues, which is unlikely to form GQs. Thus, while these “telomerase inhibitors” indeed inhibit telomerase, they are also robust inhibitors of telomeric C-strand synthesis. Furthermore, given their binding to GQ RNA and their limited specificity for GQ structures, they may disrupt many other protein–nucleic acid interactions in human cells.

Keywords

Footnotes

  • Received April 1, 2024.
  • Accepted June 10, 2024.

This article, published in RNA, is available under a Creative Commons License (Attribution 4.0 International), as described at http://creativecommons.org/licenses/by/4.0/.

Articles citing this article

| Table of Contents
OPEN ACCESS ARTICLE